Howe & Rusling Inc. Sells 795 Shares of Johnson & Johnson $JNJ

Howe & Rusling Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 3.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,146 shares of the company’s stock after selling 795 shares during the quarter. Howe & Rusling Inc.’s holdings in Johnson & Johnson were worth $3,838,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of JNJ. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $49,000. Finally, Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $50,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JNJ shares. UBS Group raised their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Citigroup raised their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Bank of America raised their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $176.29.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.5%

JNJ stock opened at $178.40 on Friday. The business has a fifty day moving average price of $170.36 and a 200 day moving average price of $161.22. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16. The stock has a market capitalization of $429.65 billion, a price-to-earnings ratio of 19.08, a P/E/G ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the firm posted $2.82 EPS. The business’s revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.